Text Size

Pharmacokinetics and Tolerability of Lu AA21004 in Child and Adolescent Patients With Depressive or Anxiety Disorder

This study is currently recruiting participants.
Verified April 2013 by H. Lundbeck A/S
Sponsor:
Information provided by (Responsible Party):
H. Lundbeck A/S
ClinicalTrials.gov Identifier:
NCT01491035
First received: November 23, 2011
Last updated: April 13, 2013
Last verified: April 2013
History of Changes
  Purpose

The study will be conducted in the USA and in Europe and will include paediatric patients diagnosed with depressive or anxiety disorders of two age populations; children aged 7-11 years and adolescents of the age 12-17 years. It is an open study to allow pharmacokinetic (PK) sampling of all patients, and four dose levels will be tested. Following lower initial doses the patients will be treated daily at the assigned dose levels for 14 days, and it is expected that patients may benefit from treatment during this period. As the treatment duration is not sufficient according to treatment guidelines, if judged or indicated by the investigator, the patients are offered to continue in an extension treatment of up to six months to allow possibility for therapeutic satisfaction.


Condition Intervention Phase
Depressive Disorder
Anxiety Disorder
 Drug: Lu AA21004
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Study Evaluating the Pharmacokinetics and Tolerability of Lu AA21004 in Connection With Multiple Oral Dosing of Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder

Resource links provided by NLM:

MedlinePlus related topics: Anxiety Depression
U.S. FDA Resources

Further study details as provided by H. Lundbeck A/S:

Primary Outcome Measures:
  • PK of Lu AA21004 and its metabolites [ Time Frame: Day 1; and Days 14-20, depending on assigned dose level ] [ Designated as safety issue: No ]
    PK parameter Cmax

  • PK of Lu AA21004 and its metabolites [ Time Frame: Day 1; and Days 14-20, depending on assigned dose level ] [ Designated as safety issue: No ]
    PK parameter AUC

  • PK of Lu AA21004 and its metabolites [ Time Frame: Day 1; and Days 14-20, depending on assigned dose level ] [ Designated as safety issue: No ]
    PK parameter t1/2

  • Safety and tolerability of Lu AA21004 [ Time Frame: From Baseline to Days 14-20, depending on assigned dose level ] [ Designated as safety issue: Yes ]
    Adverse event monitoring

  • Safety and tolerability of Lu AA21004 [ Time Frame: From Baseline to Days 14-20, depending on assigned dose level ] [ Designated as safety issue: Yes ]
    Standard clinical laboratory assessments


Estimated Enrollment: 48
Study Start Date: April 2012
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort CC1, 6 children Drug: Lu AA21004
5 mg tablets for 14 days; orally; once daily
Other Name: Vortioxetine
Experimental: Cohort CC2, 6 children Drug: Lu AA21004
10 mg tablets for 14 days (with addition of lower initial dose level); orally; once daily
Other Name: Vortioxetine
Experimental: Cohort CC3, 6 children Drug: Lu AA21004
15 mg tablets for 14 days (with addition of lower initial dose levels); orally; once daily
Other Name: Vortioxetine
Experimental: Cohort CC4, 6 children Drug: Lu AA21004
20 mg tablets for 14 days (with addition of lower initial dose levels); orally; once daily
Other Name: Vortioxetine
Experimental: Cohort AC1, 6 adolescents Drug: Lu AA21004
5 mg tablets for 14 days; orally; once daily
Other Name: Vortioxetine
Experimental: Cohort AC2, 6 adolescents Drug: Lu AA21004
10 mg tablets for 14 days (with addition of lower initial dose level); orally; once daily
Other Name: Vortioxetine
Experimental: Cohort AC3, 6 adolescents Drug: Lu AA21004
15 mg tablets for 14 days (with addition of lower initial dose levels); orally; once daily
Other Name: Vortioxetine
Experimental: Cohort AC4, 6 adolescents Drug: Lu AA21004
20 mg tablets for 14 days (with addition of lower initial dose levels); orally; once daily
Other Name: Vortioxetine

Detailed Description:

Preferably, the cohorts will be dosed in the following order: AC1, AC2, CC1, AC3, CC2, AC4, CC3, and CC4. An external data safety monitoring board (DSMB) will be established to evaluate safety, tolerability and preliminary PK data from the dosed cohort(s) prior to any dosing of subsequent cohort (s). The dose regimen may be adjusted based on the recommendation of the DSMB. Adolescents will be exposed to the Lu AA21004 each dose level before children.

  Eligibility

Ages Eligible for Study:   7 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with a DSM-IV-TR diagnosis of Depressive or Anxiety Disorder.
  • The patient and parent(s)/legal representative(s) are able to comprehend and satisfactorily comply with the protocol requirements.
  • Treatment with antidepressant therapy is warranted, as judged by the investigator.

Exclusion Criteria:

  • The patient is pregnant or breast-feeding.
  • The patient presents or has a history of an Axis I (DSM-IV-TR) diagnosis of Bipolar Disorder, Post Traumatic Stress Disorder (PTSD), Autism, Pervasive Developmental Disorder (PDD), Obsessive Compulsive Disorder (OCD) or Schizophrenia or Schizoaffective Disorder.
  • The patient has not maintained a stable dose of a methylphenidate or amphetamine for their treatment of attention-deficit/hyperactivity disorder (ADHD) for a minimum of 4 weeks prior to the study treatment.
  • The patient has a known mental retardation, or clinical evidence or known social or school history indicative of mental retardation.
  • The patient is at significant risk of committing suicide based on history (for example previous suicide attempt) or according to the investigator's experience, or based on active suicidal ideation, intent or plan, item 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS).
  • The subject has any concurrent illness that may affect the particular target or absorption, distribution, and elimination of the investigational medicinal product (IMP).
  • The patient meets DSM-IV-TR criteria for any psychoactive substance or alcohol use disorder.

Other inclusion and exclusion criteria may apply.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01491035

Contacts
Contact: Email contact via H. Lundbeck A/S LundbeckClinicalTrials@lundbeck.com

Locations
United States, District of Columbia
US003 Recruiting
Washington, District of Columbia, United States, 20010
United States, Kansas
US004 Recruiting
Wichita, Kansas, United States, 67214
United States, Ohio
US002 Recruiting
Cincinnatti, Ohio, United States, 45219
Germany
DE002 Recruiting
Berlin, Germany, 10249
DE001 Recruiting
Mainz, Germany, 55122
DE003 Active, not recruiting
Ulm, Germany, 89075
Sponsors and Collaborators
H. Lundbeck A/S
Investigators
Study Director: Email contact via H. Lundbeck A/S LundbeckClinicalTrials@lundbeck.com
  More Information

No publications provided

Responsible Party: H. Lundbeck A/S
ClinicalTrials.gov Identifier: NCT01491035     History of Changes
Other Study ID Numbers: 12708A, 2010-020170-42
Study First Received: November 23, 2011
Last Updated: April 13, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by H. Lundbeck A/S:
Children
Adolescents
Pharmacokinetic
Pharmacodynamic

Additional relevant MeSH terms:
Anxiety Disorders
Depressive Disorder
Depression
 Mental Disorders
Mood Disorders
Behavioral Symptoms

ClinicalTrials.gov processed this record on May 21, 2013